{"datetime": 1641823471, "report": {}, "sample_id": "testuser", "testuser": {"BREAST": [{"MPL c.305G>C": {"Gene Data": {"Number": 1, "Classification": "Pathogenic", "Gene": "MPL", "Exon/Intron": "1", "SNP ID": "rs28928907", "DNA change": "c.305G>C", "Protein change": "p.Arg102Pro", "Consequence": "missense_variant", "Transcript ID": "ENST00000372470.9", "Zygosity": "heterozygous", "Inheritance": "AD;AR", "Associated Disease(s)": ["essential thrombocytemia", "Congenital amegakaryocytic thrombocytopenia"], "Cancer Groups": ["BREAST", "GASTROINTESTINAL", "LUNG", "PROSTATE", "GENITOURINARY", "CNS", "FEMALE_REPRODUCTIVE", "SKIN", "ENDOCRINE", "HEMATOLOGIC", "MUSCULOSKELETAL"], "Varsome": {"gnomad_exomes": [{"version": "2.1.1", "filter": "PASS", "ac": 2, "an": 251490, "af": 7.95260248916458e-06, "ac_nfe": 2, "ac_nfe_nwe": 2, "ac_nfe_male": 1, "ac_nfe_female": 1, "ac_male": 1, "ac_female": 1, "an_afr": 16256, "an_amr": 34590, "an_asj": 10080, "an_eas": 18394, "an_eas_kor": 3818, "an_eas_jpn": 152, "an_eas_oea": 14424, "an_fin": 21644, "an_nfe": 113770, "an_nfe_bgr": 2670, "an_nfe_est": 242, "an_nfe_nwe": 42222, "an_nfe_onf": 30998, "an_nfe_seu": 11504, "an_nfe_swe": 26134, "an_oth": 6140, "an_sas": 30616, "an_afr_male": 6186, "an_amr_male": 14320, "an_asj_male": 5180, "an_eas_male": 9066, "an_fin_male": 11272, "an_nfe_male": 63610, "an_oth_male": 3212, "an_sas_male": 23072, "an_afr_female": 10070, "an_amr_female": 20270, "an_asj_female": 4900, "an_eas_female": 9328, "an_fin_female": 10372, "an_nfe_female": 50160, "an_oth_female": 2928, "an_sas_female": 7544, "an_male": 135918, "an_female": 115572, "age_hist_het_60_65": 1, "age_hist_het_65_70": 1, "variant_type": "multi-snv", "main_data": "\u0192 = 0.00000795"}], "gnomad_genomes_coverage": [{"version": "2.1", "coverage_mean": [32.013999938964844], "coverage_median": [31.0], "coverage_20_frequency": [0.935712759788812]}]}}, "Comments": [[{"clin_sig": "Pathogenic", "lab_name": "Invitae", "diseasename": " essential thrombocytemia", "comment": "This sequence change replaces arginine with proline at codon 102 of the MPL protein (p.Arg102Pro). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and proline. This variant is present in population databases (rs28928907, ExAC 0.08%). This variant has been observed on the opposite chromosome (in trans) from a pathogenic variant in individuals affected with congenital amegakaryocytic thrombocytopenia (CAMT) (PMID: 11972523, 28859041). This variant has also been observed to be homozygous or in combination with another MPL variant in several individuals affected with CAMT (PMID: 10971406, 16470591, 18240171, 19302922, 21225925, 24119002, 26854587). This finding is consistent with autosomal recessive inheritance, and suggests that this variant contributes to disease. ClinVar contains an entry for this variant (Variation ID: 14158). Experimental studies have shown that this missense change impairs trafficking of the receptor to the cell surface, glycosylation of the protein, and proliferative responses to thrombopoietin (PMID: 18422784, 19302922, 24438083, 25538044). This variant disrupts the p.Arg102 amino acid residue in MPL. Other variant(s) that disrupt this residue have been observed in individuals with MPL-related conditions (PMID: 21659346, 16470591), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.", "report_date": "2020-10-22", "labrank": "1", "selected": "false"}, {"clin_sig": "Pathogenic", "lab_name": "Invitae", "diseasename": "Congenital amegakaryocytic thrombocytopenia", "comment": "This sequence change replaces arginine with proline at codon 102 of the MPL protein (p.Arg102Pro). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and proline. This variant is present in population databases (rs28928907, ExAC 0.08%). This variant has been observed on the opposite chromosome (in trans) from a pathogenic variant in individuals affected with congenital amegakaryocytic thrombocytopenia (CAMT) (PMID: 11972523, 28859041). This variant has also been observed to be homozygous or in combination with another MPL variant in several individuals affected with CAMT (PMID: 10971406, 16470591, 18240171, 19302922, 21225925, 24119002, 26854587). This finding is consistent with autosomal recessive inheritance, and suggests that this variant contributes to disease. ClinVar contains an entry for this variant (Variation ID: 14158). Experimental studies have shown that this missense change impairs trafficking of the receptor to the cell surface, glycosylation of the protein, and proliferative responses to thrombopoietin (PMID: 18422784, 19302922, 24438083, 25538044). This variant disrupts the p.Arg102 amino acid residue in MPL. Other variant(s) that disrupt this residue have been observed in individuals with MPL-related conditions (PMID: 21659346, 16470591), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.", "report_date": "2020-10-22", "labrank": "1", "selected": "false"}, {"clin_sig": "Pathogenic", "lab_name": "Women's Health and Genetics/Laboratory Corporation of America, LabCorp", "diseasename": "Congenital amegakaryocytic thrombocytopenia", "comment": "Variant summary: The MPL c.305G>C (p.Arg102Pro) variant involves the alteration of a conserved nucleotide. 3/4 in silico tools predict a damaging outcome for this variant (SNPs&GO not captured due to low reliability index). This variant was found in 56/121606 control chromosomes at a frequency of 0.0004605, which does not exceed the estimated maximal expected allele frequency of a pathogenic MPL variant (0.002357). The variant was reported in numerous CAMPT patients in the literature, both in the homozygous and compound heterozygous state. Functional studies have shown the variant to lead to abnormal subcellular receptor distribution, lack of membrane localization, impaired glycosylation as well as impaired TPO signal transduction (Stockklausner_2015, Tijssen_2008). Taken together, this variant is classified as pathogenic.", "report_date": "2017-04-17", "labrank": "6", "selected": "false"}]], "Frequencies": {"Gene": "MPL", "Transcript": "ENST00000372470.9", "DNA change": "c.305G>C", "Protein change": "p.Arg102Pro", "Genomic Location": "chr1:43338634", "Alternate Allele Frequency": "0.04%", "dbSNP rsID": "rs28928907"}, "Publications": [{"Pubmed ID": "10971406", "Title": "Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia."}, {"Pubmed ID": "18422784", "Title": "Functional analysis of single amino-acid mutations in the thrombopoietin-receptor Mpl underlying congenital amegakaryocytic thrombocytopenia."}, {"Pubmed ID": "24728327", "Title": "Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing."}, {"Pubmed ID": "32581363", "Title": "Monogenic and polygenic inheritance become instruments for clonal selection."}]}}], "GASTROINTESTINAL": [{"MPL c.305G>C": {"Gene Data": {"Number": 1, "Classification": "Pathogenic", "Gene": "MPL", "Exon/Intron": "1", "SNP ID": "rs28928907", "DNA change": "c.305G>C", "Protein change": "p.Arg102Pro", "Consequence": "missense_variant", "Transcript ID": "ENST00000372470.9", "Zygosity": "heterozygous", "Inheritance": "AD;AR", "Associated Disease(s)": ["essential thrombocytemia", "Congenital amegakaryocytic thrombocytopenia"], "Cancer Groups": ["BREAST", "GASTROINTESTINAL", "LUNG", "PROSTATE", "GENITOURINARY", "CNS", "FEMALE_REPRODUCTIVE", "SKIN", "ENDOCRINE", "HEMATOLOGIC", "MUSCULOSKELETAL"], "Varsome": {"gnomad_exomes": [{"version": "2.1.1", "filter": "PASS", "ac": 2, "an": 251490, "af": 7.95260248916458e-06, "ac_nfe": 2, "ac_nfe_nwe": 2, "ac_nfe_male": 1, "ac_nfe_female": 1, "ac_male": 1, "ac_female": 1, "an_afr": 16256, "an_amr": 34590, "an_asj": 10080, "an_eas": 18394, "an_eas_kor": 3818, "an_eas_jpn": 152, "an_eas_oea": 14424, "an_fin": 21644, "an_nfe": 113770, "an_nfe_bgr": 2670, "an_nfe_est": 242, "an_nfe_nwe": 42222, "an_nfe_onf": 30998, "an_nfe_seu": 11504, "an_nfe_swe": 26134, "an_oth": 6140, "an_sas": 30616, "an_afr_male": 6186, "an_amr_male": 14320, "an_asj_male": 5180, "an_eas_male": 9066, "an_fin_male": 11272, "an_nfe_male": 63610, "an_oth_male": 3212, "an_sas_male": 23072, "an_afr_female": 10070, "an_amr_female": 20270, "an_asj_female": 4900, "an_eas_female": 9328, "an_fin_female": 10372, "an_nfe_female": 50160, "an_oth_female": 2928, "an_sas_female": 7544, "an_male": 135918, "an_female": 115572, "age_hist_het_60_65": 1, "age_hist_het_65_70": 1, "variant_type": "multi-snv", "main_data": "\u0192 = 0.00000795"}], "gnomad_genomes_coverage": [{"version": "2.1", "coverage_mean": [32.013999938964844], "coverage_median": [31.0], "coverage_20_frequency": [0.935712759788812]}]}}, "Comments": [[{"clin_sig": "Pathogenic", "lab_name": "Invitae", "diseasename": " essential thrombocytemia", "comment": "This sequence change replaces arginine with proline at codon 102 of the MPL protein (p.Arg102Pro). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and proline. This variant is present in population databases (rs28928907, ExAC 0.08%). This variant has been observed on the opposite chromosome (in trans) from a pathogenic variant in individuals affected with congenital amegakaryocytic thrombocytopenia (CAMT) (PMID: 11972523, 28859041). This variant has also been observed to be homozygous or in combination with another MPL variant in several individuals affected with CAMT (PMID: 10971406, 16470591, 18240171, 19302922, 21225925, 24119002, 26854587). This finding is consistent with autosomal recessive inheritance, and suggests that this variant contributes to disease. ClinVar contains an entry for this variant (Variation ID: 14158). Experimental studies have shown that this missense change impairs trafficking of the receptor to the cell surface, glycosylation of the protein, and proliferative responses to thrombopoietin (PMID: 18422784, 19302922, 24438083, 25538044). This variant disrupts the p.Arg102 amino acid residue in MPL. Other variant(s) that disrupt this residue have been observed in individuals with MPL-related conditions (PMID: 21659346, 16470591), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.", "report_date": "2020-10-22", "labrank": "1", "selected": "false"}, {"clin_sig": "Pathogenic", "lab_name": "Invitae", "diseasename": "Congenital amegakaryocytic thrombocytopenia", "comment": "This sequence change replaces arginine with proline at codon 102 of the MPL protein (p.Arg102Pro). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and proline. This variant is present in population databases (rs28928907, ExAC 0.08%). This variant has been observed on the opposite chromosome (in trans) from a pathogenic variant in individuals affected with congenital amegakaryocytic thrombocytopenia (CAMT) (PMID: 11972523, 28859041). This variant has also been observed to be homozygous or in combination with another MPL variant in several individuals affected with CAMT (PMID: 10971406, 16470591, 18240171, 19302922, 21225925, 24119002, 26854587). This finding is consistent with autosomal recessive inheritance, and suggests that this variant contributes to disease. ClinVar contains an entry for this variant (Variation ID: 14158). Experimental studies have shown that this missense change impairs trafficking of the receptor to the cell surface, glycosylation of the protein, and proliferative responses to thrombopoietin (PMID: 18422784, 19302922, 24438083, 25538044). This variant disrupts the p.Arg102 amino acid residue in MPL. Other variant(s) that disrupt this residue have been observed in individuals with MPL-related conditions (PMID: 21659346, 16470591), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.", "report_date": "2020-10-22", "labrank": "1", "selected": "false"}, {"clin_sig": "Pathogenic", "lab_name": "Women's Health and Genetics/Laboratory Corporation of America, LabCorp", "diseasename": "Congenital amegakaryocytic thrombocytopenia", "comment": "Variant summary: The MPL c.305G>C (p.Arg102Pro) variant involves the alteration of a conserved nucleotide. 3/4 in silico tools predict a damaging outcome for this variant (SNPs&GO not captured due to low reliability index). This variant was found in 56/121606 control chromosomes at a frequency of 0.0004605, which does not exceed the estimated maximal expected allele frequency of a pathogenic MPL variant (0.002357). The variant was reported in numerous CAMPT patients in the literature, both in the homozygous and compound heterozygous state. Functional studies have shown the variant to lead to abnormal subcellular receptor distribution, lack of membrane localization, impaired glycosylation as well as impaired TPO signal transduction (Stockklausner_2015, Tijssen_2008). Taken together, this variant is classified as pathogenic.", "report_date": "2017-04-17", "labrank": "6", "selected": "false"}]], "Frequencies": {"Gene": "MPL", "Transcript": "ENST00000372470.9", "DNA change": "c.305G>C", "Protein change": "p.Arg102Pro", "Genomic Location": "chr1:43338634", "Alternate Allele Frequency": "0.04%", "dbSNP rsID": "rs28928907"}, "Publications": [{"Pubmed ID": "10971406", "Title": "Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia."}, {"Pubmed ID": "18422784", "Title": "Functional analysis of single amino-acid mutations in the thrombopoietin-receptor Mpl underlying congenital amegakaryocytic thrombocytopenia."}, {"Pubmed ID": "24728327", "Title": "Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing."}, {"Pubmed ID": "32581363", "Title": "Monogenic and polygenic inheritance become instruments for clonal selection."}]}}], "LUNG": [{"MPL c.305G>C": {"Gene Data": {"Number": 1, "Classification": "Pathogenic", "Gene": "MPL", "Exon/Intron": "1", "SNP ID": "rs28928907", "DNA change": "c.305G>C", "Protein change": "p.Arg102Pro", "Consequence": "missense_variant", "Transcript ID": "ENST00000372470.9", "Zygosity": "heterozygous", "Inheritance": "AD;AR", "Associated Disease(s)": ["essential thrombocytemia", "Congenital amegakaryocytic thrombocytopenia"], "Cancer Groups": ["BREAST", "GASTROINTESTINAL", "LUNG", "PROSTATE", "GENITOURINARY", "CNS", "FEMALE_REPRODUCTIVE", "SKIN", "ENDOCRINE", "HEMATOLOGIC", "MUSCULOSKELETAL"], "Varsome": {"gnomad_exomes": [{"version": "2.1.1", "filter": "PASS", "ac": 2, "an": 251490, "af": 7.95260248916458e-06, "ac_nfe": 2, "ac_nfe_nwe": 2, "ac_nfe_male": 1, "ac_nfe_female": 1, "ac_male": 1, "ac_female": 1, "an_afr": 16256, "an_amr": 34590, "an_asj": 10080, "an_eas": 18394, "an_eas_kor": 3818, "an_eas_jpn": 152, "an_eas_oea": 14424, "an_fin": 21644, "an_nfe": 113770, "an_nfe_bgr": 2670, "an_nfe_est": 242, "an_nfe_nwe": 42222, "an_nfe_onf": 30998, "an_nfe_seu": 11504, "an_nfe_swe": 26134, "an_oth": 6140, "an_sas": 30616, "an_afr_male": 6186, "an_amr_male": 14320, "an_asj_male": 5180, "an_eas_male": 9066, "an_fin_male": 11272, "an_nfe_male": 63610, "an_oth_male": 3212, "an_sas_male": 23072, "an_afr_female": 10070, "an_amr_female": 20270, "an_asj_female": 4900, "an_eas_female": 9328, "an_fin_female": 10372, "an_nfe_female": 50160, "an_oth_female": 2928, "an_sas_female": 7544, "an_male": 135918, "an_female": 115572, "age_hist_het_60_65": 1, "age_hist_het_65_70": 1, "variant_type": "multi-snv", "main_data": "\u0192 = 0.00000795"}], "gnomad_genomes_coverage": [{"version": "2.1", "coverage_mean": [32.013999938964844], "coverage_median": [31.0], "coverage_20_frequency": [0.935712759788812]}]}}, "Comments": [[{"clin_sig": "Pathogenic", "lab_name": "Invitae", "diseasename": " essential thrombocytemia", "comment": "This sequence change replaces arginine with proline at codon 102 of the MPL protein (p.Arg102Pro). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and proline. This variant is present in population databases (rs28928907, ExAC 0.08%). This variant has been observed on the opposite chromosome (in trans) from a pathogenic variant in individuals affected with congenital amegakaryocytic thrombocytopenia (CAMT) (PMID: 11972523, 28859041). This variant has also been observed to be homozygous or in combination with another MPL variant in several individuals affected with CAMT (PMID: 10971406, 16470591, 18240171, 19302922, 21225925, 24119002, 26854587). This finding is consistent with autosomal recessive inheritance, and suggests that this variant contributes to disease. ClinVar contains an entry for this variant (Variation ID: 14158). Experimental studies have shown that this missense change impairs trafficking of the receptor to the cell surface, glycosylation of the protein, and proliferative responses to thrombopoietin (PMID: 18422784, 19302922, 24438083, 25538044). This variant disrupts the p.Arg102 amino acid residue in MPL. Other variant(s) that disrupt this residue have been observed in individuals with MPL-related conditions (PMID: 21659346, 16470591), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.", "report_date": "2020-10-22", "labrank": "1", "selected": "false"}, {"clin_sig": "Pathogenic", "lab_name": "Invitae", "diseasename": "Congenital amegakaryocytic thrombocytopenia", "comment": "This sequence change replaces arginine with proline at codon 102 of the MPL protein (p.Arg102Pro). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and proline. This variant is present in population databases (rs28928907, ExAC 0.08%). This variant has been observed on the opposite chromosome (in trans) from a pathogenic variant in individuals affected with congenital amegakaryocytic thrombocytopenia (CAMT) (PMID: 11972523, 28859041). This variant has also been observed to be homozygous or in combination with another MPL variant in several individuals affected with CAMT (PMID: 10971406, 16470591, 18240171, 19302922, 21225925, 24119002, 26854587). This finding is consistent with autosomal recessive inheritance, and suggests that this variant contributes to disease. ClinVar contains an entry for this variant (Variation ID: 14158). Experimental studies have shown that this missense change impairs trafficking of the receptor to the cell surface, glycosylation of the protein, and proliferative responses to thrombopoietin (PMID: 18422784, 19302922, 24438083, 25538044). This variant disrupts the p.Arg102 amino acid residue in MPL. Other variant(s) that disrupt this residue have been observed in individuals with MPL-related conditions (PMID: 21659346, 16470591), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.", "report_date": "2020-10-22", "labrank": "1", "selected": "false"}, {"clin_sig": "Pathogenic", "lab_name": "Women's Health and Genetics/Laboratory Corporation of America, LabCorp", "diseasename": "Congenital amegakaryocytic thrombocytopenia", "comment": "Variant summary: The MPL c.305G>C (p.Arg102Pro) variant involves the alteration of a conserved nucleotide. 3/4 in silico tools predict a damaging outcome for this variant (SNPs&GO not captured due to low reliability index). This variant was found in 56/121606 control chromosomes at a frequency of 0.0004605, which does not exceed the estimated maximal expected allele frequency of a pathogenic MPL variant (0.002357). The variant was reported in numerous CAMPT patients in the literature, both in the homozygous and compound heterozygous state. Functional studies have shown the variant to lead to abnormal subcellular receptor distribution, lack of membrane localization, impaired glycosylation as well as impaired TPO signal transduction (Stockklausner_2015, Tijssen_2008). Taken together, this variant is classified as pathogenic.", "report_date": "2017-04-17", "labrank": "6", "selected": "false"}]], "Frequencies": {"Gene": "MPL", "Transcript": "ENST00000372470.9", "DNA change": "c.305G>C", "Protein change": "p.Arg102Pro", "Genomic Location": "chr1:43338634", "Alternate Allele Frequency": "0.04%", "dbSNP rsID": "rs28928907"}, "Publications": [{"Pubmed ID": "10971406", "Title": "Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia."}, {"Pubmed ID": "18422784", "Title": "Functional analysis of single amino-acid mutations in the thrombopoietin-receptor Mpl underlying congenital amegakaryocytic thrombocytopenia."}, {"Pubmed ID": "24728327", "Title": "Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing."}, {"Pubmed ID": "32581363", "Title": "Monogenic and polygenic inheritance become instruments for clonal selection."}]}}], "PROSTATE": [{"MPL c.305G>C": {"Gene Data": {"Number": 1, "Classification": "Pathogenic", "Gene": "MPL", "Exon/Intron": "1", "SNP ID": "rs28928907", "DNA change": "c.305G>C", "Protein change": "p.Arg102Pro", "Consequence": "missense_variant", "Transcript ID": "ENST00000372470.9", "Zygosity": "heterozygous", "Inheritance": "AD;AR", "Associated Disease(s)": ["essential thrombocytemia", "Congenital amegakaryocytic thrombocytopenia"], "Cancer Groups": ["BREAST", "GASTROINTESTINAL", "LUNG", "PROSTATE", "GENITOURINARY", "CNS", "FEMALE_REPRODUCTIVE", "SKIN", "ENDOCRINE", "HEMATOLOGIC", "MUSCULOSKELETAL"], "Varsome": {"gnomad_exomes": [{"version": "2.1.1", "filter": "PASS", "ac": 2, "an": 251490, "af": 7.95260248916458e-06, "ac_nfe": 2, "ac_nfe_nwe": 2, "ac_nfe_male": 1, "ac_nfe_female": 1, "ac_male": 1, "ac_female": 1, "an_afr": 16256, "an_amr": 34590, "an_asj": 10080, "an_eas": 18394, "an_eas_kor": 3818, "an_eas_jpn": 152, "an_eas_oea": 14424, "an_fin": 21644, "an_nfe": 113770, "an_nfe_bgr": 2670, "an_nfe_est": 242, "an_nfe_nwe": 42222, "an_nfe_onf": 30998, "an_nfe_seu": 11504, "an_nfe_swe": 26134, "an_oth": 6140, "an_sas": 30616, "an_afr_male": 6186, "an_amr_male": 14320, "an_asj_male": 5180, "an_eas_male": 9066, "an_fin_male": 11272, "an_nfe_male": 63610, "an_oth_male": 3212, "an_sas_male": 23072, "an_afr_female": 10070, "an_amr_female": 20270, "an_asj_female": 4900, "an_eas_female": 9328, "an_fin_female": 10372, "an_nfe_female": 50160, "an_oth_female": 2928, "an_sas_female": 7544, "an_male": 135918, "an_female": 115572, "age_hist_het_60_65": 1, "age_hist_het_65_70": 1, "variant_type": "multi-snv", "main_data": "\u0192 = 0.00000795"}], "gnomad_genomes_coverage": [{"version": "2.1", "coverage_mean": [32.013999938964844], "coverage_median": [31.0], "coverage_20_frequency": [0.935712759788812]}]}}, "Comments": [[{"clin_sig": "Pathogenic", "lab_name": "Invitae", "diseasename": " essential thrombocytemia", "comment": "This sequence change replaces arginine with proline at codon 102 of the MPL protein (p.Arg102Pro). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and proline. This variant is present in population databases (rs28928907, ExAC 0.08%). This variant has been observed on the opposite chromosome (in trans) from a pathogenic variant in individuals affected with congenital amegakaryocytic thrombocytopenia (CAMT) (PMID: 11972523, 28859041). This variant has also been observed to be homozygous or in combination with another MPL variant in several individuals affected with CAMT (PMID: 10971406, 16470591, 18240171, 19302922, 21225925, 24119002, 26854587). This finding is consistent with autosomal recessive inheritance, and suggests that this variant contributes to disease. ClinVar contains an entry for this variant (Variation ID: 14158). Experimental studies have shown that this missense change impairs trafficking of the receptor to the cell surface, glycosylation of the protein, and proliferative responses to thrombopoietin (PMID: 18422784, 19302922, 24438083, 25538044). This variant disrupts the p.Arg102 amino acid residue in MPL. Other variant(s) that disrupt this residue have been observed in individuals with MPL-related conditions (PMID: 21659346, 16470591), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.", "report_date": "2020-10-22", "labrank": "1", "selected": "false"}, {"clin_sig": "Pathogenic", "lab_name": "Invitae", "diseasename": "Congenital amegakaryocytic thrombocytopenia", "comment": "This sequence change replaces arginine with proline at codon 102 of the MPL protein (p.Arg102Pro). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and proline. This variant is present in population databases (rs28928907, ExAC 0.08%). This variant has been observed on the opposite chromosome (in trans) from a pathogenic variant in individuals affected with congenital amegakaryocytic thrombocytopenia (CAMT) (PMID: 11972523, 28859041). This variant has also been observed to be homozygous or in combination with another MPL variant in several individuals affected with CAMT (PMID: 10971406, 16470591, 18240171, 19302922, 21225925, 24119002, 26854587). This finding is consistent with autosomal recessive inheritance, and suggests that this variant contributes to disease. ClinVar contains an entry for this variant (Variation ID: 14158). Experimental studies have shown that this missense change impairs trafficking of the receptor to the cell surface, glycosylation of the protein, and proliferative responses to thrombopoietin (PMID: 18422784, 19302922, 24438083, 25538044). This variant disrupts the p.Arg102 amino acid residue in MPL. Other variant(s) that disrupt this residue have been observed in individuals with MPL-related conditions (PMID: 21659346, 16470591), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.", "report_date": "2020-10-22", "labrank": "1", "selected": "false"}, {"clin_sig": "Pathogenic", "lab_name": "Women's Health and Genetics/Laboratory Corporation of America, LabCorp", "diseasename": "Congenital amegakaryocytic thrombocytopenia", "comment": "Variant summary: The MPL c.305G>C (p.Arg102Pro) variant involves the alteration of a conserved nucleotide. 3/4 in silico tools predict a damaging outcome for this variant (SNPs&GO not captured due to low reliability index). This variant was found in 56/121606 control chromosomes at a frequency of 0.0004605, which does not exceed the estimated maximal expected allele frequency of a pathogenic MPL variant (0.002357). The variant was reported in numerous CAMPT patients in the literature, both in the homozygous and compound heterozygous state. Functional studies have shown the variant to lead to abnormal subcellular receptor distribution, lack of membrane localization, impaired glycosylation as well as impaired TPO signal transduction (Stockklausner_2015, Tijssen_2008). Taken together, this variant is classified as pathogenic.", "report_date": "2017-04-17", "labrank": "6", "selected": "false"}]], "Frequencies": {"Gene": "MPL", "Transcript": "ENST00000372470.9", "DNA change": "c.305G>C", "Protein change": "p.Arg102Pro", "Genomic Location": "chr1:43338634", "Alternate Allele Frequency": "0.04%", "dbSNP rsID": "rs28928907"}, "Publications": [{"Pubmed ID": "10971406", "Title": "Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia."}, {"Pubmed ID": "18422784", "Title": "Functional analysis of single amino-acid mutations in the thrombopoietin-receptor Mpl underlying congenital amegakaryocytic thrombocytopenia."}, {"Pubmed ID": "24728327", "Title": "Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing."}, {"Pubmed ID": "32581363", "Title": "Monogenic and polygenic inheritance become instruments for clonal selection."}]}}], "GENITOURINARY": [{"MPL c.305G>C": {"Gene Data": {"Number": 1, "Classification": "Pathogenic", "Gene": "MPL", "Exon/Intron": "1", "SNP ID": "rs28928907", "DNA change": "c.305G>C", "Protein change": "p.Arg102Pro", "Consequence": "missense_variant", "Transcript ID": "ENST00000372470.9", "Zygosity": "heterozygous", "Inheritance": "AD;AR", "Associated Disease(s)": ["essential thrombocytemia", "Congenital amegakaryocytic thrombocytopenia"], "Cancer Groups": ["BREAST", "GASTROINTESTINAL", "LUNG", "PROSTATE", "GENITOURINARY", "CNS", "FEMALE_REPRODUCTIVE", "SKIN", "ENDOCRINE", "HEMATOLOGIC", "MUSCULOSKELETAL"], "Varsome": {"gnomad_exomes": [{"version": "2.1.1", "filter": "PASS", "ac": 2, "an": 251490, "af": 7.95260248916458e-06, "ac_nfe": 2, "ac_nfe_nwe": 2, "ac_nfe_male": 1, "ac_nfe_female": 1, "ac_male": 1, "ac_female": 1, "an_afr": 16256, "an_amr": 34590, "an_asj": 10080, "an_eas": 18394, "an_eas_kor": 3818, "an_eas_jpn": 152, "an_eas_oea": 14424, "an_fin": 21644, "an_nfe": 113770, "an_nfe_bgr": 2670, "an_nfe_est": 242, "an_nfe_nwe": 42222, "an_nfe_onf": 30998, "an_nfe_seu": 11504, "an_nfe_swe": 26134, "an_oth": 6140, "an_sas": 30616, "an_afr_male": 6186, "an_amr_male": 14320, "an_asj_male": 5180, "an_eas_male": 9066, "an_fin_male": 11272, "an_nfe_male": 63610, "an_oth_male": 3212, "an_sas_male": 23072, "an_afr_female": 10070, "an_amr_female": 20270, "an_asj_female": 4900, "an_eas_female": 9328, "an_fin_female": 10372, "an_nfe_female": 50160, "an_oth_female": 2928, "an_sas_female": 7544, "an_male": 135918, "an_female": 115572, "age_hist_het_60_65": 1, "age_hist_het_65_70": 1, "variant_type": "multi-snv", "main_data": "\u0192 = 0.00000795"}], "gnomad_genomes_coverage": [{"version": "2.1", "coverage_mean": [32.013999938964844], "coverage_median": [31.0], "coverage_20_frequency": [0.935712759788812]}]}}, "Comments": [[{"clin_sig": "Pathogenic", "lab_name": "Invitae", "diseasename": " essential thrombocytemia", "comment": "This sequence change replaces arginine with proline at codon 102 of the MPL protein (p.Arg102Pro). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and proline. This variant is present in population databases (rs28928907, ExAC 0.08%). This variant has been observed on the opposite chromosome (in trans) from a pathogenic variant in individuals affected with congenital amegakaryocytic thrombocytopenia (CAMT) (PMID: 11972523, 28859041). This variant has also been observed to be homozygous or in combination with another MPL variant in several individuals affected with CAMT (PMID: 10971406, 16470591, 18240171, 19302922, 21225925, 24119002, 26854587). This finding is consistent with autosomal recessive inheritance, and suggests that this variant contributes to disease. ClinVar contains an entry for this variant (Variation ID: 14158). Experimental studies have shown that this missense change impairs trafficking of the receptor to the cell surface, glycosylation of the protein, and proliferative responses to thrombopoietin (PMID: 18422784, 19302922, 24438083, 25538044). This variant disrupts the p.Arg102 amino acid residue in MPL. Other variant(s) that disrupt this residue have been observed in individuals with MPL-related conditions (PMID: 21659346, 16470591), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.", "report_date": "2020-10-22", "labrank": "1", "selected": "false"}, {"clin_sig": "Pathogenic", "lab_name": "Invitae", "diseasename": "Congenital amegakaryocytic thrombocytopenia", "comment": "This sequence change replaces arginine with proline at codon 102 of the MPL protein (p.Arg102Pro). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and proline. This variant is present in population databases (rs28928907, ExAC 0.08%). This variant has been observed on the opposite chromosome (in trans) from a pathogenic variant in individuals affected with congenital amegakaryocytic thrombocytopenia (CAMT) (PMID: 11972523, 28859041). This variant has also been observed to be homozygous or in combination with another MPL variant in several individuals affected with CAMT (PMID: 10971406, 16470591, 18240171, 19302922, 21225925, 24119002, 26854587). This finding is consistent with autosomal recessive inheritance, and suggests that this variant contributes to disease. ClinVar contains an entry for this variant (Variation ID: 14158). Experimental studies have shown that this missense change impairs trafficking of the receptor to the cell surface, glycosylation of the protein, and proliferative responses to thrombopoietin (PMID: 18422784, 19302922, 24438083, 25538044). This variant disrupts the p.Arg102 amino acid residue in MPL. Other variant(s) that disrupt this residue have been observed in individuals with MPL-related conditions (PMID: 21659346, 16470591), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.", "report_date": "2020-10-22", "labrank": "1", "selected": "false"}, {"clin_sig": "Pathogenic", "lab_name": "Women's Health and Genetics/Laboratory Corporation of America, LabCorp", "diseasename": "Congenital amegakaryocytic thrombocytopenia", "comment": "Variant summary: The MPL c.305G>C (p.Arg102Pro) variant involves the alteration of a conserved nucleotide. 3/4 in silico tools predict a damaging outcome for this variant (SNPs&GO not captured due to low reliability index). This variant was found in 56/121606 control chromosomes at a frequency of 0.0004605, which does not exceed the estimated maximal expected allele frequency of a pathogenic MPL variant (0.002357). The variant was reported in numerous CAMPT patients in the literature, both in the homozygous and compound heterozygous state. Functional studies have shown the variant to lead to abnormal subcellular receptor distribution, lack of membrane localization, impaired glycosylation as well as impaired TPO signal transduction (Stockklausner_2015, Tijssen_2008). Taken together, this variant is classified as pathogenic.", "report_date": "2017-04-17", "labrank": "6", "selected": "false"}]], "Frequencies": {"Gene": "MPL", "Transcript": "ENST00000372470.9", "DNA change": "c.305G>C", "Protein change": "p.Arg102Pro", "Genomic Location": "chr1:43338634", "Alternate Allele Frequency": "0.04%", "dbSNP rsID": "rs28928907"}, "Publications": [{"Pubmed ID": "10971406", "Title": "Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia."}, {"Pubmed ID": "18422784", "Title": "Functional analysis of single amino-acid mutations in the thrombopoietin-receptor Mpl underlying congenital amegakaryocytic thrombocytopenia."}, {"Pubmed ID": "24728327", "Title": "Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing."}, {"Pubmed ID": "32581363", "Title": "Monogenic and polygenic inheritance become instruments for clonal selection."}]}}], "CNS": [{"MPL c.305G>C": {"Gene Data": {"Number": 1, "Classification": "Pathogenic", "Gene": "MPL", "Exon/Intron": "1", "SNP ID": "rs28928907", "DNA change": "c.305G>C", "Protein change": "p.Arg102Pro", "Consequence": "missense_variant", "Transcript ID": "ENST00000372470.9", "Zygosity": "heterozygous", "Inheritance": "AD;AR", "Associated Disease(s)": ["essential thrombocytemia", "Congenital amegakaryocytic thrombocytopenia"], "Cancer Groups": ["BREAST", "GASTROINTESTINAL", "LUNG", "PROSTATE", "GENITOURINARY", "CNS", "FEMALE_REPRODUCTIVE", "SKIN", "ENDOCRINE", "HEMATOLOGIC", "MUSCULOSKELETAL"], "Varsome": {"gnomad_exomes": [{"version": "2.1.1", "filter": "PASS", "ac": 2, "an": 251490, "af": 7.95260248916458e-06, "ac_nfe": 2, "ac_nfe_nwe": 2, "ac_nfe_male": 1, "ac_nfe_female": 1, "ac_male": 1, "ac_female": 1, "an_afr": 16256, "an_amr": 34590, "an_asj": 10080, "an_eas": 18394, "an_eas_kor": 3818, "an_eas_jpn": 152, "an_eas_oea": 14424, "an_fin": 21644, "an_nfe": 113770, "an_nfe_bgr": 2670, "an_nfe_est": 242, "an_nfe_nwe": 42222, "an_nfe_onf": 30998, "an_nfe_seu": 11504, "an_nfe_swe": 26134, "an_oth": 6140, "an_sas": 30616, "an_afr_male": 6186, "an_amr_male": 14320, "an_asj_male": 5180, "an_eas_male": 9066, "an_fin_male": 11272, "an_nfe_male": 63610, "an_oth_male": 3212, "an_sas_male": 23072, "an_afr_female": 10070, "an_amr_female": 20270, "an_asj_female": 4900, "an_eas_female": 9328, "an_fin_female": 10372, "an_nfe_female": 50160, "an_oth_female": 2928, "an_sas_female": 7544, "an_male": 135918, "an_female": 115572, "age_hist_het_60_65": 1, "age_hist_het_65_70": 1, "variant_type": "multi-snv", "main_data": "\u0192 = 0.00000795"}], "gnomad_genomes_coverage": [{"version": "2.1", "coverage_mean": [32.013999938964844], "coverage_median": [31.0], "coverage_20_frequency": [0.935712759788812]}]}}, "Comments": [[{"clin_sig": "Pathogenic", "lab_name": "Invitae", "diseasename": " essential thrombocytemia", "comment": "This sequence change replaces arginine with proline at codon 102 of the MPL protein (p.Arg102Pro). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and proline. This variant is present in population databases (rs28928907, ExAC 0.08%). This variant has been observed on the opposite chromosome (in trans) from a pathogenic variant in individuals affected with congenital amegakaryocytic thrombocytopenia (CAMT) (PMID: 11972523, 28859041). This variant has also been observed to be homozygous or in combination with another MPL variant in several individuals affected with CAMT (PMID: 10971406, 16470591, 18240171, 19302922, 21225925, 24119002, 26854587). This finding is consistent with autosomal recessive inheritance, and suggests that this variant contributes to disease. ClinVar contains an entry for this variant (Variation ID: 14158). Experimental studies have shown that this missense change impairs trafficking of the receptor to the cell surface, glycosylation of the protein, and proliferative responses to thrombopoietin (PMID: 18422784, 19302922, 24438083, 25538044). This variant disrupts the p.Arg102 amino acid residue in MPL. Other variant(s) that disrupt this residue have been observed in individuals with MPL-related conditions (PMID: 21659346, 16470591), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.", "report_date": "2020-10-22", "labrank": "1", "selected": "false"}, {"clin_sig": "Pathogenic", "lab_name": "Invitae", "diseasename": "Congenital amegakaryocytic thrombocytopenia", "comment": "This sequence change replaces arginine with proline at codon 102 of the MPL protein (p.Arg102Pro). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and proline. This variant is present in population databases (rs28928907, ExAC 0.08%). This variant has been observed on the opposite chromosome (in trans) from a pathogenic variant in individuals affected with congenital amegakaryocytic thrombocytopenia (CAMT) (PMID: 11972523, 28859041). This variant has also been observed to be homozygous or in combination with another MPL variant in several individuals affected with CAMT (PMID: 10971406, 16470591, 18240171, 19302922, 21225925, 24119002, 26854587). This finding is consistent with autosomal recessive inheritance, and suggests that this variant contributes to disease. ClinVar contains an entry for this variant (Variation ID: 14158). Experimental studies have shown that this missense change impairs trafficking of the receptor to the cell surface, glycosylation of the protein, and proliferative responses to thrombopoietin (PMID: 18422784, 19302922, 24438083, 25538044). This variant disrupts the p.Arg102 amino acid residue in MPL. Other variant(s) that disrupt this residue have been observed in individuals with MPL-related conditions (PMID: 21659346, 16470591), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.", "report_date": "2020-10-22", "labrank": "1", "selected": "false"}, {"clin_sig": "Pathogenic", "lab_name": "Women's Health and Genetics/Laboratory Corporation of America, LabCorp", "diseasename": "Congenital amegakaryocytic thrombocytopenia", "comment": "Variant summary: The MPL c.305G>C (p.Arg102Pro) variant involves the alteration of a conserved nucleotide. 3/4 in silico tools predict a damaging outcome for this variant (SNPs&GO not captured due to low reliability index). This variant was found in 56/121606 control chromosomes at a frequency of 0.0004605, which does not exceed the estimated maximal expected allele frequency of a pathogenic MPL variant (0.002357). The variant was reported in numerous CAMPT patients in the literature, both in the homozygous and compound heterozygous state. Functional studies have shown the variant to lead to abnormal subcellular receptor distribution, lack of membrane localization, impaired glycosylation as well as impaired TPO signal transduction (Stockklausner_2015, Tijssen_2008). Taken together, this variant is classified as pathogenic.", "report_date": "2017-04-17", "labrank": "6", "selected": "false"}]], "Frequencies": {"Gene": "MPL", "Transcript": "ENST00000372470.9", "DNA change": "c.305G>C", "Protein change": "p.Arg102Pro", "Genomic Location": "chr1:43338634", "Alternate Allele Frequency": "0.04%", "dbSNP rsID": "rs28928907"}, "Publications": [{"Pubmed ID": "10971406", "Title": "Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia."}, {"Pubmed ID": "18422784", "Title": "Functional analysis of single amino-acid mutations in the thrombopoietin-receptor Mpl underlying congenital amegakaryocytic thrombocytopenia."}, {"Pubmed ID": "24728327", "Title": "Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing."}, {"Pubmed ID": "32581363", "Title": "Monogenic and polygenic inheritance become instruments for clonal selection."}]}}], "FEMALE_REPRODUCTIVE": [{"MPL c.305G>C": {"Gene Data": {"Number": 1, "Classification": "Pathogenic", "Gene": "MPL", "Exon/Intron": "1", "SNP ID": "rs28928907", "DNA change": "c.305G>C", "Protein change": "p.Arg102Pro", "Consequence": "missense_variant", "Transcript ID": "ENST00000372470.9", "Zygosity": "heterozygous", "Inheritance": "AD;AR", "Associated Disease(s)": ["essential thrombocytemia", "Congenital amegakaryocytic thrombocytopenia"], "Cancer Groups": ["BREAST", "GASTROINTESTINAL", "LUNG", "PROSTATE", "GENITOURINARY", "CNS", "FEMALE_REPRODUCTIVE", "SKIN", "ENDOCRINE", "HEMATOLOGIC", "MUSCULOSKELETAL"], "Varsome": {"gnomad_exomes": [{"version": "2.1.1", "filter": "PASS", "ac": 2, "an": 251490, "af": 7.95260248916458e-06, "ac_nfe": 2, "ac_nfe_nwe": 2, "ac_nfe_male": 1, "ac_nfe_female": 1, "ac_male": 1, "ac_female": 1, "an_afr": 16256, "an_amr": 34590, "an_asj": 10080, "an_eas": 18394, "an_eas_kor": 3818, "an_eas_jpn": 152, "an_eas_oea": 14424, "an_fin": 21644, "an_nfe": 113770, "an_nfe_bgr": 2670, "an_nfe_est": 242, "an_nfe_nwe": 42222, "an_nfe_onf": 30998, "an_nfe_seu": 11504, "an_nfe_swe": 26134, "an_oth": 6140, "an_sas": 30616, "an_afr_male": 6186, "an_amr_male": 14320, "an_asj_male": 5180, "an_eas_male": 9066, "an_fin_male": 11272, "an_nfe_male": 63610, "an_oth_male": 3212, "an_sas_male": 23072, "an_afr_female": 10070, "an_amr_female": 20270, "an_asj_female": 4900, "an_eas_female": 9328, "an_fin_female": 10372, "an_nfe_female": 50160, "an_oth_female": 2928, "an_sas_female": 7544, "an_male": 135918, "an_female": 115572, "age_hist_het_60_65": 1, "age_hist_het_65_70": 1, "variant_type": "multi-snv", "main_data": "\u0192 = 0.00000795"}], "gnomad_genomes_coverage": [{"version": "2.1", "coverage_mean": [32.013999938964844], "coverage_median": [31.0], "coverage_20_frequency": [0.935712759788812]}]}}, "Comments": [[{"clin_sig": "Pathogenic", "lab_name": "Invitae", "diseasename": " essential thrombocytemia", "comment": "This sequence change replaces arginine with proline at codon 102 of the MPL protein (p.Arg102Pro). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and proline. This variant is present in population databases (rs28928907, ExAC 0.08%). This variant has been observed on the opposite chromosome (in trans) from a pathogenic variant in individuals affected with congenital amegakaryocytic thrombocytopenia (CAMT) (PMID: 11972523, 28859041). This variant has also been observed to be homozygous or in combination with another MPL variant in several individuals affected with CAMT (PMID: 10971406, 16470591, 18240171, 19302922, 21225925, 24119002, 26854587). This finding is consistent with autosomal recessive inheritance, and suggests that this variant contributes to disease. ClinVar contains an entry for this variant (Variation ID: 14158). Experimental studies have shown that this missense change impairs trafficking of the receptor to the cell surface, glycosylation of the protein, and proliferative responses to thrombopoietin (PMID: 18422784, 19302922, 24438083, 25538044). This variant disrupts the p.Arg102 amino acid residue in MPL. Other variant(s) that disrupt this residue have been observed in individuals with MPL-related conditions (PMID: 21659346, 16470591), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.", "report_date": "2020-10-22", "labrank": "1", "selected": "false"}, {"clin_sig": "Pathogenic", "lab_name": "Invitae", "diseasename": "Congenital amegakaryocytic thrombocytopenia", "comment": "This sequence change replaces arginine with proline at codon 102 of the MPL protein (p.Arg102Pro). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and proline. This variant is present in population databases (rs28928907, ExAC 0.08%). This variant has been observed on the opposite chromosome (in trans) from a pathogenic variant in individuals affected with congenital amegakaryocytic thrombocytopenia (CAMT) (PMID: 11972523, 28859041). This variant has also been observed to be homozygous or in combination with another MPL variant in several individuals affected with CAMT (PMID: 10971406, 16470591, 18240171, 19302922, 21225925, 24119002, 26854587). This finding is consistent with autosomal recessive inheritance, and suggests that this variant contributes to disease. ClinVar contains an entry for this variant (Variation ID: 14158). Experimental studies have shown that this missense change impairs trafficking of the receptor to the cell surface, glycosylation of the protein, and proliferative responses to thrombopoietin (PMID: 18422784, 19302922, 24438083, 25538044). This variant disrupts the p.Arg102 amino acid residue in MPL. Other variant(s) that disrupt this residue have been observed in individuals with MPL-related conditions (PMID: 21659346, 16470591), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.", "report_date": "2020-10-22", "labrank": "1", "selected": "false"}, {"clin_sig": "Pathogenic", "lab_name": "Women's Health and Genetics/Laboratory Corporation of America, LabCorp", "diseasename": "Congenital amegakaryocytic thrombocytopenia", "comment": "Variant summary: The MPL c.305G>C (p.Arg102Pro) variant involves the alteration of a conserved nucleotide. 3/4 in silico tools predict a damaging outcome for this variant (SNPs&GO not captured due to low reliability index). This variant was found in 56/121606 control chromosomes at a frequency of 0.0004605, which does not exceed the estimated maximal expected allele frequency of a pathogenic MPL variant (0.002357). The variant was reported in numerous CAMPT patients in the literature, both in the homozygous and compound heterozygous state. Functional studies have shown the variant to lead to abnormal subcellular receptor distribution, lack of membrane localization, impaired glycosylation as well as impaired TPO signal transduction (Stockklausner_2015, Tijssen_2008). Taken together, this variant is classified as pathogenic.", "report_date": "2017-04-17", "labrank": "6", "selected": "false"}]], "Frequencies": {"Gene": "MPL", "Transcript": "ENST00000372470.9", "DNA change": "c.305G>C", "Protein change": "p.Arg102Pro", "Genomic Location": "chr1:43338634", "Alternate Allele Frequency": "0.04%", "dbSNP rsID": "rs28928907"}, "Publications": [{"Pubmed ID": "10971406", "Title": "Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia."}, {"Pubmed ID": "18422784", "Title": "Functional analysis of single amino-acid mutations in the thrombopoietin-receptor Mpl underlying congenital amegakaryocytic thrombocytopenia."}, {"Pubmed ID": "24728327", "Title": "Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing."}, {"Pubmed ID": "32581363", "Title": "Monogenic and polygenic inheritance become instruments for clonal selection."}]}}], "SKIN": [{"MPL c.305G>C": {"Gene Data": {"Number": 1, "Classification": "Pathogenic", "Gene": "MPL", "Exon/Intron": "1", "SNP ID": "rs28928907", "DNA change": "c.305G>C", "Protein change": "p.Arg102Pro", "Consequence": "missense_variant", "Transcript ID": "ENST00000372470.9", "Zygosity": "heterozygous", "Inheritance": "AD;AR", "Associated Disease(s)": ["essential thrombocytemia", "Congenital amegakaryocytic thrombocytopenia"], "Cancer Groups": ["BREAST", "GASTROINTESTINAL", "LUNG", "PROSTATE", "GENITOURINARY", "CNS", "FEMALE_REPRODUCTIVE", "SKIN", "ENDOCRINE", "HEMATOLOGIC", "MUSCULOSKELETAL"], "Varsome": {"gnomad_exomes": [{"version": "2.1.1", "filter": "PASS", "ac": 2, "an": 251490, "af": 7.95260248916458e-06, "ac_nfe": 2, "ac_nfe_nwe": 2, "ac_nfe_male": 1, "ac_nfe_female": 1, "ac_male": 1, "ac_female": 1, "an_afr": 16256, "an_amr": 34590, "an_asj": 10080, "an_eas": 18394, "an_eas_kor": 3818, "an_eas_jpn": 152, "an_eas_oea": 14424, "an_fin": 21644, "an_nfe": 113770, "an_nfe_bgr": 2670, "an_nfe_est": 242, "an_nfe_nwe": 42222, "an_nfe_onf": 30998, "an_nfe_seu": 11504, "an_nfe_swe": 26134, "an_oth": 6140, "an_sas": 30616, "an_afr_male": 6186, "an_amr_male": 14320, "an_asj_male": 5180, "an_eas_male": 9066, "an_fin_male": 11272, "an_nfe_male": 63610, "an_oth_male": 3212, "an_sas_male": 23072, "an_afr_female": 10070, "an_amr_female": 20270, "an_asj_female": 4900, "an_eas_female": 9328, "an_fin_female": 10372, "an_nfe_female": 50160, "an_oth_female": 2928, "an_sas_female": 7544, "an_male": 135918, "an_female": 115572, "age_hist_het_60_65": 1, "age_hist_het_65_70": 1, "variant_type": "multi-snv", "main_data": "\u0192 = 0.00000795"}], "gnomad_genomes_coverage": [{"version": "2.1", "coverage_mean": [32.013999938964844], "coverage_median": [31.0], "coverage_20_frequency": [0.935712759788812]}]}}, "Comments": [[{"clin_sig": "Pathogenic", "lab_name": "Invitae", "diseasename": " essential thrombocytemia", "comment": "This sequence change replaces arginine with proline at codon 102 of the MPL protein (p.Arg102Pro). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and proline. This variant is present in population databases (rs28928907, ExAC 0.08%). This variant has been observed on the opposite chromosome (in trans) from a pathogenic variant in individuals affected with congenital amegakaryocytic thrombocytopenia (CAMT) (PMID: 11972523, 28859041). This variant has also been observed to be homozygous or in combination with another MPL variant in several individuals affected with CAMT (PMID: 10971406, 16470591, 18240171, 19302922, 21225925, 24119002, 26854587). This finding is consistent with autosomal recessive inheritance, and suggests that this variant contributes to disease. ClinVar contains an entry for this variant (Variation ID: 14158). Experimental studies have shown that this missense change impairs trafficking of the receptor to the cell surface, glycosylation of the protein, and proliferative responses to thrombopoietin (PMID: 18422784, 19302922, 24438083, 25538044). This variant disrupts the p.Arg102 amino acid residue in MPL. Other variant(s) that disrupt this residue have been observed in individuals with MPL-related conditions (PMID: 21659346, 16470591), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.", "report_date": "2020-10-22", "labrank": "1", "selected": "false"}, {"clin_sig": "Pathogenic", "lab_name": "Invitae", "diseasename": "Congenital amegakaryocytic thrombocytopenia", "comment": "This sequence change replaces arginine with proline at codon 102 of the MPL protein (p.Arg102Pro). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and proline. This variant is present in population databases (rs28928907, ExAC 0.08%). This variant has been observed on the opposite chromosome (in trans) from a pathogenic variant in individuals affected with congenital amegakaryocytic thrombocytopenia (CAMT) (PMID: 11972523, 28859041). This variant has also been observed to be homozygous or in combination with another MPL variant in several individuals affected with CAMT (PMID: 10971406, 16470591, 18240171, 19302922, 21225925, 24119002, 26854587). This finding is consistent with autosomal recessive inheritance, and suggests that this variant contributes to disease. ClinVar contains an entry for this variant (Variation ID: 14158). Experimental studies have shown that this missense change impairs trafficking of the receptor to the cell surface, glycosylation of the protein, and proliferative responses to thrombopoietin (PMID: 18422784, 19302922, 24438083, 25538044). This variant disrupts the p.Arg102 amino acid residue in MPL. Other variant(s) that disrupt this residue have been observed in individuals with MPL-related conditions (PMID: 21659346, 16470591), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.", "report_date": "2020-10-22", "labrank": "1", "selected": "false"}, {"clin_sig": "Pathogenic", "lab_name": "Women's Health and Genetics/Laboratory Corporation of America, LabCorp", "diseasename": "Congenital amegakaryocytic thrombocytopenia", "comment": "Variant summary: The MPL c.305G>C (p.Arg102Pro) variant involves the alteration of a conserved nucleotide. 3/4 in silico tools predict a damaging outcome for this variant (SNPs&GO not captured due to low reliability index). This variant was found in 56/121606 control chromosomes at a frequency of 0.0004605, which does not exceed the estimated maximal expected allele frequency of a pathogenic MPL variant (0.002357). The variant was reported in numerous CAMPT patients in the literature, both in the homozygous and compound heterozygous state. Functional studies have shown the variant to lead to abnormal subcellular receptor distribution, lack of membrane localization, impaired glycosylation as well as impaired TPO signal transduction (Stockklausner_2015, Tijssen_2008). Taken together, this variant is classified as pathogenic.", "report_date": "2017-04-17", "labrank": "6", "selected": "false"}]], "Frequencies": {"Gene": "MPL", "Transcript": "ENST00000372470.9", "DNA change": "c.305G>C", "Protein change": "p.Arg102Pro", "Genomic Location": "chr1:43338634", "Alternate Allele Frequency": "0.04%", "dbSNP rsID": "rs28928907"}, "Publications": [{"Pubmed ID": "10971406", "Title": "Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia."}, {"Pubmed ID": "18422784", "Title": "Functional analysis of single amino-acid mutations in the thrombopoietin-receptor Mpl underlying congenital amegakaryocytic thrombocytopenia."}, {"Pubmed ID": "24728327", "Title": "Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing."}, {"Pubmed ID": "32581363", "Title": "Monogenic and polygenic inheritance become instruments for clonal selection."}]}}], "ENDOCRINE": [{"MPL c.305G>C": {"Gene Data": {"Number": 1, "Classification": "Pathogenic", "Gene": "MPL", "Exon/Intron": "1", "SNP ID": "rs28928907", "DNA change": "c.305G>C", "Protein change": "p.Arg102Pro", "Consequence": "missense_variant", "Transcript ID": "ENST00000372470.9", "Zygosity": "heterozygous", "Inheritance": "AD;AR", "Associated Disease(s)": ["essential thrombocytemia", "Congenital amegakaryocytic thrombocytopenia"], "Cancer Groups": ["BREAST", "GASTROINTESTINAL", "LUNG", "PROSTATE", "GENITOURINARY", "CNS", "FEMALE_REPRODUCTIVE", "SKIN", "ENDOCRINE", "HEMATOLOGIC", "MUSCULOSKELETAL"], "Varsome": {"gnomad_exomes": [{"version": "2.1.1", "filter": "PASS", "ac": 2, "an": 251490, "af": 7.95260248916458e-06, "ac_nfe": 2, "ac_nfe_nwe": 2, "ac_nfe_male": 1, "ac_nfe_female": 1, "ac_male": 1, "ac_female": 1, "an_afr": 16256, "an_amr": 34590, "an_asj": 10080, "an_eas": 18394, "an_eas_kor": 3818, "an_eas_jpn": 152, "an_eas_oea": 14424, "an_fin": 21644, "an_nfe": 113770, "an_nfe_bgr": 2670, "an_nfe_est": 242, "an_nfe_nwe": 42222, "an_nfe_onf": 30998, "an_nfe_seu": 11504, "an_nfe_swe": 26134, "an_oth": 6140, "an_sas": 30616, "an_afr_male": 6186, "an_amr_male": 14320, "an_asj_male": 5180, "an_eas_male": 9066, "an_fin_male": 11272, "an_nfe_male": 63610, "an_oth_male": 3212, "an_sas_male": 23072, "an_afr_female": 10070, "an_amr_female": 20270, "an_asj_female": 4900, "an_eas_female": 9328, "an_fin_female": 10372, "an_nfe_female": 50160, "an_oth_female": 2928, "an_sas_female": 7544, "an_male": 135918, "an_female": 115572, "age_hist_het_60_65": 1, "age_hist_het_65_70": 1, "variant_type": "multi-snv", "main_data": "\u0192 = 0.00000795"}], "gnomad_genomes_coverage": [{"version": "2.1", "coverage_mean": [32.013999938964844], "coverage_median": [31.0], "coverage_20_frequency": [0.935712759788812]}]}}, "Comments": [[{"clin_sig": "Pathogenic", "lab_name": "Invitae", "diseasename": " essential thrombocytemia", "comment": "This sequence change replaces arginine with proline at codon 102 of the MPL protein (p.Arg102Pro). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and proline. This variant is present in population databases (rs28928907, ExAC 0.08%). This variant has been observed on the opposite chromosome (in trans) from a pathogenic variant in individuals affected with congenital amegakaryocytic thrombocytopenia (CAMT) (PMID: 11972523, 28859041). This variant has also been observed to be homozygous or in combination with another MPL variant in several individuals affected with CAMT (PMID: 10971406, 16470591, 18240171, 19302922, 21225925, 24119002, 26854587). This finding is consistent with autosomal recessive inheritance, and suggests that this variant contributes to disease. ClinVar contains an entry for this variant (Variation ID: 14158). Experimental studies have shown that this missense change impairs trafficking of the receptor to the cell surface, glycosylation of the protein, and proliferative responses to thrombopoietin (PMID: 18422784, 19302922, 24438083, 25538044). This variant disrupts the p.Arg102 amino acid residue in MPL. Other variant(s) that disrupt this residue have been observed in individuals with MPL-related conditions (PMID: 21659346, 16470591), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.", "report_date": "2020-10-22", "labrank": "1", "selected": "false"}, {"clin_sig": "Pathogenic", "lab_name": "Invitae", "diseasename": "Congenital amegakaryocytic thrombocytopenia", "comment": "This sequence change replaces arginine with proline at codon 102 of the MPL protein (p.Arg102Pro). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and proline. This variant is present in population databases (rs28928907, ExAC 0.08%). This variant has been observed on the opposite chromosome (in trans) from a pathogenic variant in individuals affected with congenital amegakaryocytic thrombocytopenia (CAMT) (PMID: 11972523, 28859041). This variant has also been observed to be homozygous or in combination with another MPL variant in several individuals affected with CAMT (PMID: 10971406, 16470591, 18240171, 19302922, 21225925, 24119002, 26854587). This finding is consistent with autosomal recessive inheritance, and suggests that this variant contributes to disease. ClinVar contains an entry for this variant (Variation ID: 14158). Experimental studies have shown that this missense change impairs trafficking of the receptor to the cell surface, glycosylation of the protein, and proliferative responses to thrombopoietin (PMID: 18422784, 19302922, 24438083, 25538044). This variant disrupts the p.Arg102 amino acid residue in MPL. Other variant(s) that disrupt this residue have been observed in individuals with MPL-related conditions (PMID: 21659346, 16470591), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.", "report_date": "2020-10-22", "labrank": "1", "selected": "false"}, {"clin_sig": "Pathogenic", "lab_name": "Women's Health and Genetics/Laboratory Corporation of America, LabCorp", "diseasename": "Congenital amegakaryocytic thrombocytopenia", "comment": "Variant summary: The MPL c.305G>C (p.Arg102Pro) variant involves the alteration of a conserved nucleotide. 3/4 in silico tools predict a damaging outcome for this variant (SNPs&GO not captured due to low reliability index). This variant was found in 56/121606 control chromosomes at a frequency of 0.0004605, which does not exceed the estimated maximal expected allele frequency of a pathogenic MPL variant (0.002357). The variant was reported in numerous CAMPT patients in the literature, both in the homozygous and compound heterozygous state. Functional studies have shown the variant to lead to abnormal subcellular receptor distribution, lack of membrane localization, impaired glycosylation as well as impaired TPO signal transduction (Stockklausner_2015, Tijssen_2008). Taken together, this variant is classified as pathogenic.", "report_date": "2017-04-17", "labrank": "6", "selected": "false"}]], "Frequencies": {"Gene": "MPL", "Transcript": "ENST00000372470.9", "DNA change": "c.305G>C", "Protein change": "p.Arg102Pro", "Genomic Location": "chr1:43338634", "Alternate Allele Frequency": "0.04%", "dbSNP rsID": "rs28928907"}, "Publications": [{"Pubmed ID": "10971406", "Title": "Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia."}, {"Pubmed ID": "18422784", "Title": "Functional analysis of single amino-acid mutations in the thrombopoietin-receptor Mpl underlying congenital amegakaryocytic thrombocytopenia."}, {"Pubmed ID": "24728327", "Title": "Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing."}, {"Pubmed ID": "32581363", "Title": "Monogenic and polygenic inheritance become instruments for clonal selection."}]}}], "HEMATOLOGIC": [{"MPL c.305G>C": {"Gene Data": {"Number": 1, "Classification": "Pathogenic", "Gene": "MPL", "Exon/Intron": "1", "SNP ID": "rs28928907", "DNA change": "c.305G>C", "Protein change": "p.Arg102Pro", "Consequence": "missense_variant", "Transcript ID": "ENST00000372470.9", "Zygosity": "heterozygous", "Inheritance": "AD;AR", "Associated Disease(s)": ["essential thrombocytemia", "Congenital amegakaryocytic thrombocytopenia"], "Cancer Groups": ["BREAST", "GASTROINTESTINAL", "LUNG", "PROSTATE", "GENITOURINARY", "CNS", "FEMALE_REPRODUCTIVE", "SKIN", "ENDOCRINE", "HEMATOLOGIC", "MUSCULOSKELETAL"], "Varsome": {"gnomad_exomes": [{"version": "2.1.1", "filter": "PASS", "ac": 2, "an": 251490, "af": 7.95260248916458e-06, "ac_nfe": 2, "ac_nfe_nwe": 2, "ac_nfe_male": 1, "ac_nfe_female": 1, "ac_male": 1, "ac_female": 1, "an_afr": 16256, "an_amr": 34590, "an_asj": 10080, "an_eas": 18394, "an_eas_kor": 3818, "an_eas_jpn": 152, "an_eas_oea": 14424, "an_fin": 21644, "an_nfe": 113770, "an_nfe_bgr": 2670, "an_nfe_est": 242, "an_nfe_nwe": 42222, "an_nfe_onf": 30998, "an_nfe_seu": 11504, "an_nfe_swe": 26134, "an_oth": 6140, "an_sas": 30616, "an_afr_male": 6186, "an_amr_male": 14320, "an_asj_male": 5180, "an_eas_male": 9066, "an_fin_male": 11272, "an_nfe_male": 63610, "an_oth_male": 3212, "an_sas_male": 23072, "an_afr_female": 10070, "an_amr_female": 20270, "an_asj_female": 4900, "an_eas_female": 9328, "an_fin_female": 10372, "an_nfe_female": 50160, "an_oth_female": 2928, "an_sas_female": 7544, "an_male": 135918, "an_female": 115572, "age_hist_het_60_65": 1, "age_hist_het_65_70": 1, "variant_type": "multi-snv", "main_data": "\u0192 = 0.00000795"}], "gnomad_genomes_coverage": [{"version": "2.1", "coverage_mean": [32.013999938964844], "coverage_median": [31.0], "coverage_20_frequency": [0.935712759788812]}]}}, "Comments": [[{"clin_sig": "Pathogenic", "lab_name": "Invitae", "diseasename": " essential thrombocytemia", "comment": "This sequence change replaces arginine with proline at codon 102 of the MPL protein (p.Arg102Pro). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and proline. This variant is present in population databases (rs28928907, ExAC 0.08%). This variant has been observed on the opposite chromosome (in trans) from a pathogenic variant in individuals affected with congenital amegakaryocytic thrombocytopenia (CAMT) (PMID: 11972523, 28859041). This variant has also been observed to be homozygous or in combination with another MPL variant in several individuals affected with CAMT (PMID: 10971406, 16470591, 18240171, 19302922, 21225925, 24119002, 26854587). This finding is consistent with autosomal recessive inheritance, and suggests that this variant contributes to disease. ClinVar contains an entry for this variant (Variation ID: 14158). Experimental studies have shown that this missense change impairs trafficking of the receptor to the cell surface, glycosylation of the protein, and proliferative responses to thrombopoietin (PMID: 18422784, 19302922, 24438083, 25538044). This variant disrupts the p.Arg102 amino acid residue in MPL. Other variant(s) that disrupt this residue have been observed in individuals with MPL-related conditions (PMID: 21659346, 16470591), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.", "report_date": "2020-10-22", "labrank": "1", "selected": "false"}, {"clin_sig": "Pathogenic", "lab_name": "Invitae", "diseasename": "Congenital amegakaryocytic thrombocytopenia", "comment": "This sequence change replaces arginine with proline at codon 102 of the MPL protein (p.Arg102Pro). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and proline. This variant is present in population databases (rs28928907, ExAC 0.08%). This variant has been observed on the opposite chromosome (in trans) from a pathogenic variant in individuals affected with congenital amegakaryocytic thrombocytopenia (CAMT) (PMID: 11972523, 28859041). This variant has also been observed to be homozygous or in combination with another MPL variant in several individuals affected with CAMT (PMID: 10971406, 16470591, 18240171, 19302922, 21225925, 24119002, 26854587). This finding is consistent with autosomal recessive inheritance, and suggests that this variant contributes to disease. ClinVar contains an entry for this variant (Variation ID: 14158). Experimental studies have shown that this missense change impairs trafficking of the receptor to the cell surface, glycosylation of the protein, and proliferative responses to thrombopoietin (PMID: 18422784, 19302922, 24438083, 25538044). This variant disrupts the p.Arg102 amino acid residue in MPL. Other variant(s) that disrupt this residue have been observed in individuals with MPL-related conditions (PMID: 21659346, 16470591), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.", "report_date": "2020-10-22", "labrank": "1", "selected": "false"}, {"clin_sig": "Pathogenic", "lab_name": "Women's Health and Genetics/Laboratory Corporation of America, LabCorp", "diseasename": "Congenital amegakaryocytic thrombocytopenia", "comment": "Variant summary: The MPL c.305G>C (p.Arg102Pro) variant involves the alteration of a conserved nucleotide. 3/4 in silico tools predict a damaging outcome for this variant (SNPs&GO not captured due to low reliability index). This variant was found in 56/121606 control chromosomes at a frequency of 0.0004605, which does not exceed the estimated maximal expected allele frequency of a pathogenic MPL variant (0.002357). The variant was reported in numerous CAMPT patients in the literature, both in the homozygous and compound heterozygous state. Functional studies have shown the variant to lead to abnormal subcellular receptor distribution, lack of membrane localization, impaired glycosylation as well as impaired TPO signal transduction (Stockklausner_2015, Tijssen_2008). Taken together, this variant is classified as pathogenic.", "report_date": "2017-04-17", "labrank": "6", "selected": "false"}]], "Frequencies": {"Gene": "MPL", "Transcript": "ENST00000372470.9", "DNA change": "c.305G>C", "Protein change": "p.Arg102Pro", "Genomic Location": "chr1:43338634", "Alternate Allele Frequency": "0.04%", "dbSNP rsID": "rs28928907"}, "Publications": [{"Pubmed ID": "10971406", "Title": "Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia."}, {"Pubmed ID": "18422784", "Title": "Functional analysis of single amino-acid mutations in the thrombopoietin-receptor Mpl underlying congenital amegakaryocytic thrombocytopenia."}, {"Pubmed ID": "24728327", "Title": "Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing."}, {"Pubmed ID": "32581363", "Title": "Monogenic and polygenic inheritance become instruments for clonal selection."}]}}], "MUSCULOSKELETAL": [{"MPL c.305G>C": {"Gene Data": {"Number": 1, "Classification": "Pathogenic", "Gene": "MPL", "Exon/Intron": "1", "SNP ID": "rs28928907", "DNA change": "c.305G>C", "Protein change": "p.Arg102Pro", "Consequence": "missense_variant", "Transcript ID": "ENST00000372470.9", "Zygosity": "heterozygous", "Inheritance": "AD;AR", "Associated Disease(s)": ["essential thrombocytemia", "Congenital amegakaryocytic thrombocytopenia"], "Cancer Groups": ["BREAST", "GASTROINTESTINAL", "LUNG", "PROSTATE", "GENITOURINARY", "CNS", "FEMALE_REPRODUCTIVE", "SKIN", "ENDOCRINE", "HEMATOLOGIC", "MUSCULOSKELETAL"], "Varsome": {"gnomad_exomes": [{"version": "2.1.1", "filter": "PASS", "ac": 2, "an": 251490, "af": 7.95260248916458e-06, "ac_nfe": 2, "ac_nfe_nwe": 2, "ac_nfe_male": 1, "ac_nfe_female": 1, "ac_male": 1, "ac_female": 1, "an_afr": 16256, "an_amr": 34590, "an_asj": 10080, "an_eas": 18394, "an_eas_kor": 3818, "an_eas_jpn": 152, "an_eas_oea": 14424, "an_fin": 21644, "an_nfe": 113770, "an_nfe_bgr": 2670, "an_nfe_est": 242, "an_nfe_nwe": 42222, "an_nfe_onf": 30998, "an_nfe_seu": 11504, "an_nfe_swe": 26134, "an_oth": 6140, "an_sas": 30616, "an_afr_male": 6186, "an_amr_male": 14320, "an_asj_male": 5180, "an_eas_male": 9066, "an_fin_male": 11272, "an_nfe_male": 63610, "an_oth_male": 3212, "an_sas_male": 23072, "an_afr_female": 10070, "an_amr_female": 20270, "an_asj_female": 4900, "an_eas_female": 9328, "an_fin_female": 10372, "an_nfe_female": 50160, "an_oth_female": 2928, "an_sas_female": 7544, "an_male": 135918, "an_female": 115572, "age_hist_het_60_65": 1, "age_hist_het_65_70": 1, "variant_type": "multi-snv", "main_data": "\u0192 = 0.00000795"}], "gnomad_genomes_coverage": [{"version": "2.1", "coverage_mean": [32.013999938964844], "coverage_median": [31.0], "coverage_20_frequency": [0.935712759788812]}]}}, "Comments": [[{"clin_sig": "Pathogenic", "lab_name": "Invitae", "diseasename": " essential thrombocytemia", "comment": "This sequence change replaces arginine with proline at codon 102 of the MPL protein (p.Arg102Pro). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and proline. This variant is present in population databases (rs28928907, ExAC 0.08%). This variant has been observed on the opposite chromosome (in trans) from a pathogenic variant in individuals affected with congenital amegakaryocytic thrombocytopenia (CAMT) (PMID: 11972523, 28859041). This variant has also been observed to be homozygous or in combination with another MPL variant in several individuals affected with CAMT (PMID: 10971406, 16470591, 18240171, 19302922, 21225925, 24119002, 26854587). This finding is consistent with autosomal recessive inheritance, and suggests that this variant contributes to disease. ClinVar contains an entry for this variant (Variation ID: 14158). Experimental studies have shown that this missense change impairs trafficking of the receptor to the cell surface, glycosylation of the protein, and proliferative responses to thrombopoietin (PMID: 18422784, 19302922, 24438083, 25538044). This variant disrupts the p.Arg102 amino acid residue in MPL. Other variant(s) that disrupt this residue have been observed in individuals with MPL-related conditions (PMID: 21659346, 16470591), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.", "report_date": "2020-10-22", "labrank": "1", "selected": "false"}, {"clin_sig": "Pathogenic", "lab_name": "Invitae", "diseasename": "Congenital amegakaryocytic thrombocytopenia", "comment": "This sequence change replaces arginine with proline at codon 102 of the MPL protein (p.Arg102Pro). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and proline. This variant is present in population databases (rs28928907, ExAC 0.08%). This variant has been observed on the opposite chromosome (in trans) from a pathogenic variant in individuals affected with congenital amegakaryocytic thrombocytopenia (CAMT) (PMID: 11972523, 28859041). This variant has also been observed to be homozygous or in combination with another MPL variant in several individuals affected with CAMT (PMID: 10971406, 16470591, 18240171, 19302922, 21225925, 24119002, 26854587). This finding is consistent with autosomal recessive inheritance, and suggests that this variant contributes to disease. ClinVar contains an entry for this variant (Variation ID: 14158). Experimental studies have shown that this missense change impairs trafficking of the receptor to the cell surface, glycosylation of the protein, and proliferative responses to thrombopoietin (PMID: 18422784, 19302922, 24438083, 25538044). This variant disrupts the p.Arg102 amino acid residue in MPL. Other variant(s) that disrupt this residue have been observed in individuals with MPL-related conditions (PMID: 21659346, 16470591), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.", "report_date": "2020-10-22", "labrank": "1", "selected": "false"}, {"clin_sig": "Pathogenic", "lab_name": "Women's Health and Genetics/Laboratory Corporation of America, LabCorp", "diseasename": "Congenital amegakaryocytic thrombocytopenia", "comment": "Variant summary: The MPL c.305G>C (p.Arg102Pro) variant involves the alteration of a conserved nucleotide. 3/4 in silico tools predict a damaging outcome for this variant (SNPs&GO not captured due to low reliability index). This variant was found in 56/121606 control chromosomes at a frequency of 0.0004605, which does not exceed the estimated maximal expected allele frequency of a pathogenic MPL variant (0.002357). The variant was reported in numerous CAMPT patients in the literature, both in the homozygous and compound heterozygous state. Functional studies have shown the variant to lead to abnormal subcellular receptor distribution, lack of membrane localization, impaired glycosylation as well as impaired TPO signal transduction (Stockklausner_2015, Tijssen_2008). Taken together, this variant is classified as pathogenic.", "report_date": "2017-04-17", "labrank": "6", "selected": "false"}]], "Frequencies": {"Gene": "MPL", "Transcript": "ENST00000372470.9", "DNA change": "c.305G>C", "Protein change": "p.Arg102Pro", "Genomic Location": "chr1:43338634", "Alternate Allele Frequency": "0.04%", "dbSNP rsID": "rs28928907"}, "Publications": [{"Pubmed ID": "10971406", "Title": "Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia."}, {"Pubmed ID": "18422784", "Title": "Functional analysis of single amino-acid mutations in the thrombopoietin-receptor Mpl underlying congenital amegakaryocytic thrombocytopenia."}, {"Pubmed ID": "24728327", "Title": "Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing."}, {"Pubmed ID": "32581363", "Title": "Monogenic and polygenic inheritance become instruments for clonal selection."}]}}]}}